Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture

• US 4,859,765 A
• Filed: 07/06/1984
• Issued: 08/22/1989
• Est. Priority Date: 10/17/1983
• Status: Expired due to Fees

• Current Assignee: Syntec Incorporated (Atos SE)
• Original Assignee: Syntec Incorporated (Atos SE)
• Inventors: Moffatt, John G., Nestor, John J. Jr., Chan, Hardy W.
• Primary Examiner(s): NOT, DEFINED
• Application Number:
  US06/628,678
• Time in Patent Office: 1,873 Days
• Field of Search: 260/112.5 R, 260/112.5 E, 530/326, 530/327, 530/328, 530/329, 530/333
• US Class Current: 530/333
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: C07K 14/61 Growth hormone [GH], i.e. somatotropin
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
• CPC Class Codes: Y10S 930/12 Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
• CPC Class Codes: Y10S 930/26 Containing cys-cys disulfide bridge between nonadjacent cysteine residues

Abstract

The present invention relates to novel synthetic antigens, conjugates and antibodies based upon specific peptide sequences and the production thereof. More particularly, the invention relates to a polypeptide which is a determinant site of a protein, the polypeptide having from 8 to 20 amino acid residues, having an amino-terminal amino acid and a carboxyl-terminal amino acid, wherein the polypeptide includes:

(a) a four amino acid sequence which corresponds to the four amino acid sequence of a β-turn of the protein;

(b) a sequence of two to eight amino acid residues attached to the amino terminal (H₂ N--) of the four amino acid sequence; and

(c) a sequence of two to eight amino acid residues attached to the carboxyl terminal (--COOH) of the four amino acid sequence,

wherein the amino acid residues of subparts (b) and (c) correspond to those attached to the amino terminal and the carboxyl terminal, respectively of the β-turn of the protein, and the pharmaceutically acceptable salts of the polypeptide. The invention relates to a conjugate which comprises the polypeptide described above with a macromolecular carrier. The invention also relates to antibodies and the production thereof which are specific for the polypeptide or the conjugate of the peptide described above.

The synthetic polypeptide sequences, peptide conjugates and antibodies thereof are useful as antigens in the production of vaccines, antiviral agents, diagnostic reagents and the like, for the detection and treatment of infectious and immune diseases such as polio and cancer, and the like in mammals, particularly human beings.

Claims

1. A method of producing a synthetic antigenic polypeptide from a protein having a predetermined sequence of amino acids, said method comprising the steps of:

(1) determining a predicted β

-turn polypeptide sequence consisting of four amino acid residues of the protein, said β

-turn sequence having two ends; and

(2) synthesizing a polypeptide segment of the protein, wherein said segment comprises the β

-turn sequence and from two to eight amino acid residues on each end of the β

-turn sequence.

2. The method of claim 1 which further includes the step of conjugating said polypeptide with a macromolecular carrier.

4. The method of claim 1 wherein the four amino acid sequence of the β

-turn has a calculated probability greater than or equal to 0.75×

10^-4.

3. A synthetic antigenic polypeptide which is a determinant site of a protein, said polypeptide consisting of from 8 to 20 amino acid residues, having an amino-terminal amino acid and a carboxyl-terminal amino acid, wherein said polypeptide includes:

(a) a four amino acid sequence which corresponds to the four amino acid sequence of a predicted β

-turn of said protein;

(b) a sequence of two to eight amino acid residues attached to the amino terminal of said four amino acid sequence; and

(c) a sequence of two to eight amino acid residues attached to the carboxyl terminal of said four amino acid sequence;

wherein the amino acid residues of subparts (b) and (c) correspond to those attached to the amino terminal and the carboxyl terminal, respectively of the β

-turn of said protein, or a pharmaceutically acceptable salt of said polypeptide.

5. The polypeptide of claim 3 wherein the four amino acid sequence of the β

-turn has a calculated probability greater than or equal to 0.75×

10^-4.